ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for discussion Regístrate para interactuar en nuestros foros activos para discutir con inversores de ideas afines.
Eagle Capital Growth Fund Inc

Eagle Capital Growth Fund Inc (GRF)

9.9157
0.0656
(0.67%)
Cerrado 30 Enero 3:00PM
9.9157
0.00
(0.00%)
Fuera de horario: 3:00PM

Discusiones en tiempo real e ideas comerciales: opere con confianza con nuestra poderosa plataforma.

Estadísticas y detalles clave

Último Precio
9.9157
Postura de Compra
-
Postura de Venta
-
Volume Operado de la Acción
457
9.76 Rango del Día 10.01
8.78 Rango de 52 semanas 10.99
Capitalización de Mercado [m]
Precio Anterior
9.8501
Precio de Apertura
10.01
Última hora de negociación
Volumen financiero
US$ 4,483
Precio Promedio Ponderado
9.8086
Volumen promedio (3 m)
6,772
Acciones en circulación
3,967,836
Rendimiento del Dividendo
6.86%
Ratio Precio/Utilidad
8.53
Beneficio por acción (BPA)
1.16
turnover
736k
Beneficio neto
4.61M

Acerca de Eagle Capital Growth Fund Inc

The Fund's objective is long-term growth utilizing the concept of total return for selecting investments. The Fund's objective is long-term growth utilizing the concept of total return for selecting investments.

Sector
Unit Inv Tr, Closed-end Mgmt
Industria
Unit Inv Tr, Closed-end Mgmt
Sede
Lutherville Timonium, Maryland, USA
Fundado
-
Eagle Capital Growth Fund Inc is listed in the Unit Inv Tr, Closed-end Mgmt sector of the American Stock Exchange with ticker GRF. The last closing price for Eagle Capital Growth was US$9.85. Over the last year, Eagle Capital Growth shares have traded in a share price range of US$ 8.78 to US$ 10.99.

Eagle Capital Growth currently has 3,967,836 shares in issue. The market capitalisation of Eagle Capital Growth is US$39.08 million. Eagle Capital Growth has a price to earnings ratio (PE ratio) of 8.53.

GRF Últimas noticias

Grifols Pioneers High-Tech Analysis of Plasma Bank to Detect Early Signs of Parkinson’s Disease

‘Chronos-PD’ is looking for biological signals that could indicate increased chance of developing Parkinson’s disease (PD) years before symptoms appear, leading to new diagnostic tools and...

GigaGen Doses First Patient in Phase 1 Trial of Recombinant Polyclonal Drug Candidate, GIGA-2339, for Hepatitis B Virus

SAN CARLOS, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- GigaGen Inc., a biotechnology company advancing transformative antibody drugs for immunodeficiencies, infectious diseases and...

Eagle Capital Growth Fund Declares Year-End Distribution of $0.68 Per Share in Cash

The Eagle Capital Growth Fund, Inc. (“Fund”) (NYSE American: GRF) today declared a year-end distribution of $0.68 per share in cash. The record date for this distribution is November 29, 2024...

Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to hemostasisGrifols surgical bleeding management...

Grifols Partners with BARDA for Proof-of-Concept Testing of Ocular Immunoglobulin as Treatment for Sulfur Mustard-Induced Eye Injury

Initiative will test Grifols ocular surface immunoglobulin (OSIG) eye drops to evaluate their nonclinical efficacy in neutralizing symptoms from exposure to sulfur mustard, a chemical warfare...

GigaGen Awarded U.S. BARDA Contract to Develop Recombinant Polyclonal Antibody Therapies for Botulinum Neurotoxins and an Additional Biothreat

The contract will provide an initial commitment of $19.6 million and up to $135.2 million over a six-year period, supporting drug manufacturing and phase 1 trials for the two programs GigaGen’s...

Período †Variación(Ptos)Variación %AperturaPrecio MáximoPrecio MínimoAvg. Vol. diarioPrecio Promedio Ponderado
1-0.1402-1.394206386310.055910.06929.667809.75504099CS
40.27572.859958506229.6410.06929.1730949.64271524CS
12-0.2343-2.3083743842410.1510.998.8567729.9441484CS
260.37573.938155136279.5410.998.8550809.84541025CS
520.965710.78994413418.9510.998.7839179.65614093CS
156-0.2043-2.0187747035610.1211.257.845459.13035917CS
2602.065726.31464968157.8511.255.249198.57581488CS

GRF - Preguntas Frecuentes

¿Cuál es el precio actual de las acciones de Eagle Capital Growth?
El precio actual de las acciones de Eagle Capital Growth es US$ 9.9157
¿Cuántas acciones de Eagle Capital Growth están en circulación?
Eagle Capital Growth tiene 3,967,836 acciones en circulación
¿Cuál es la capitalización de mercado de Eagle Capital Growth?
La capitalización de mercado de Eagle Capital Growth es USD 39.08M
¿Cuál es el rango de negociación de 1 año para el precio de las acciones de Eagle Capital Growth?
Eagle Capital Growth ha negociado en un rango de US$ 8.78 a US$ 10.99 durante el último año
¿Cuál es el ratio PE (precio/beneficio) de Eagle Capital Growth?
El ratio precio/beneficio de Eagle Capital Growth es 8.53
¿Cuál es el ratio de efectivo a ventas de Eagle Capital Growth?
El ratio de efectivo a ventas de Eagle Capital Growth es 53.48
¿Cuál es la moneda de reporte de Eagle Capital Growth?
Eagle Capital Growth presenta sus resultados financieros en USD
¿Cuál es el último ingresos anual de Eagle Capital Growth?
El último ingresos anual de Eagle Capital Growth es USD 736k
¿Cuál es el último beneficio anual de Eagle Capital Growth?
El último beneficio anual de Eagle Capital Growth es USD 4.61M
¿Cuál es la dirección registrada de Eagle Capital Growth?
La dirección registrada de Eagle Capital Growth es 2405 YORK ROAD, SUITE 201, LUTHERVILLE TIMONIUM, MARYLAND, 21093 2264
¿En qué sector industrial opera Eagle Capital Growth?
Eagle Capital Growth opera en el sector UNIT INV TR, CLOSED-END MGMT

Movimientos

Ver todo
  • Volumen
  • % Mayores Alzas
  • % Mayores Bajas
SímboloPrecioVol.
FOXOFOXO Technologies Inc
US$ 0.2553
(14.28%)
6.55M
RIOXDefiance Daily Target 2x Long Riot ETF
US$ 23.44
(11.30%)
220.52k
AUSTAustin Gold Corp
US$ 1.31
(11.02%)
416.41k
CHROChannel Therapeutics Corporation
US$ 2.44
(10.91%)
121.02k
ZONECleanCore Solutions Inc
US$ 1.0762
(9.82%)
39.76k
SGNSigning Day Sports Inc
US$ 2.56
(-41.01%)
3.07M
EXODExodus Movement Inc
US$ 58.96
(-33.98%)
203.24k
DXFEason Technology Limited
US$ 16.53
(-28.04%)
214.42k
OSTXOS Therapies Incorporated
US$ 1.95
(-23.53%)
741.05k
PMNTPerfect Moment Ltd
US$ 0.69
(-18.83%)
113.71k
TSLZT Rex 2X Inverse Tesla Daily Target ETF
US$ 2.3599
(-6.17%)
119.52M
SOXLDirexion Daily Semiconductor Bull 3X Shares
US$ 27.15
(5.72%)
86.38M
NVDQT Rex 2X Inverse NVIDIA Daily Target ETF
US$ 3.32
(-1.19%)
80.8M
FXIiShares China Large Cap
US$ 32.59
(2.39%)
66.66M
XLFFinancial Select Sector
US$ 51.77
(0.96%)
63.42M
weedtrader420 weedtrader420 8 minutos hace
BITCOIN BCH $140,000 FEBRUARY TARGET Pink Floyd - MONEY
BTCUSD
Whalatane Whalatane 8 minutos hace
UNCY is supposed to have a commercialization plan presented this Qt .
The Co needs to ramp up but and be ready to roll as soon as OLC is approved . The time line for the TDAPA process ...which is CMS payments beginning is at best 3 mths from approval .
Some recent examples
For
UNCY
Dodger1 Dodger1 8 minutos hace
could be spoon bending time...go... $AABB
AABB
Top Penny Top Penny 8 minutos hace
I'm having a few drinks tonight listening to the devils violinist, I am retired thanks to plays like $PSRU!

https://www.youtube.com/watch?v=vihq22xpl1A
PSRU
wickw50 wickw50 11 minutos hace
$60.00 as of the last filing...
ETEK
Jack_of_All_Trades Jack_of_All_Trades 11 minutos hace
I don't know. You're the f@cking expert. You've devoted your entire pathetic life to this shit.

I'm not even trying to be funny when I say this but the other day I saw a crow eating garbage in a parking lot and I literally thought of you.

RDAR
RDAR
weedtrader420 weedtrader420 15 minutos hace
XRP ETF no more lawsuit ✊😎☝️ WOOHOOOOOO next level up 🪙🪙Hotel California
XRPUSD
MasterBlastr MasterBlastr 20 minutos hace
Meaningless since a true supply/demand dynamic isn't operating.
XRPUSD
alertmeipp alertmeipp 20 minutos hace
The real upside lies in RSV and Enanta’s shift toward becoming an immunology-focused company. Mavyret remains a factor, but the real potential comes from these strategic moves. If executed well, this could be a great setup—we’ll see how it unfolds in the next few quarters.

The waiting
ENTA
Nanotoday Nanotoday 22 minutos hace
I’m not sure why, but I can’t believe you are still a believer. Now, more than ever, you have to admit I was right all along. Or couldn’t you care less?
NNVC
DJPele DJPele 22 minutos hace
Since our patience is starting to grow weary, I figured I would remind everyone of the last 10Q's highlights and what's in store here soon:

Overview

During the first nine months of 2024, the Company continued its progress on multiple fronts, including the following.
NWBO
ace65 ace65 26 minutos hace
$13 volume
ATWT
Money4Nothing-M4N Money4Nothing-M4N 28 minutos hace
CRISPR platforms can result in off-target modifications, unwanted on-target modifications, and genomic rearrangements.

Kim switched to a non-crispr knock in/knock out method. The knock-in knock-out technology allows KBL to work with more complex protein sequences, which are about four
KBLB
Nebuchadnezzar Nebuchadnezzar 28 minutos hace
RITE (Mineral Rite)

https://mineral-rite.com/investor-relations/

https://www.otcmarkets.com/stock/RITE/disclosure

https://x.com/mineralrite/status/1884771921897853390?s=46


read up on this one. if things go as some say, RITE will be
littlejohn littlejohn 29 minutos hace
SMCI has the 33.06 gap down from Friday

01/24 that could fill quick in a price

upturn...44.09 next gap down area...

Around 32.5 was the simple moving price

average when gap down happened...

It happened with 2 selling days, Th
NVDA SMCI
Top Penny Top Penny 29 minutos hace
Share reductions forthcoming!

https://investorshub.advfn.com/uimage/uploads/2017/5/1/fxbnpMoving-picture-money-stacking-up-gif-animation.gif
PSRU
3331 3331 35 minutos hace
Despite showing essentially no effectiveness in a Phase 2 study for LSR - Suzetrigine showed a mean reduction of 2.02 points on the NPRS at week 12, compared to a 1.98 point reduction in the placebo group - the FDA just approved it. Go Figure!

The near-identical reduction to placebo
VRTX
ace65 ace65 35 minutos hace
I too ...but i have been buying down here to try and recoup a little.
Seems to be going up.
DGWR
dstock07734 dstock07734 35 minutos hace
Bro,

I repeatedly mentioned about why it cannot be mRNA and listed all the reasons. In terms of immunotherapy, who has better judgement? Larry Ellison or Baker Brothers?

Now read this again. I am only allowed one post a day and I want to save my one post to some fake l
NWBO
CelestialOgre14 CelestialOgre14 35 minutos hace
positive momentum will keep building up till earnings day, we will be flying to the moon.
0.90$ in 2 weeks
ELTP
sirant sirant 36 minutos hace
I believe Ben will take care of the shareholders. JMHO 

GO $MCIC 
MCIC
BasedOnFeels BasedOnFeels 37 minutos hace
This guy gets it!
This had to be brought back to life after a hissy fit removal too? Comedy.
Geeeeeeeez what a wah wah.

Elituv is owed over 1.2 million dollars minimum. Still waiting to see what compensation he gets for giving up control too. 6.5B is alot left to dilut
TWOH
thistraderknowsall thistraderknowsall 37 minutos hace
***MAJOR BREAKOUT *** mentions MOBILE #1 On Top5 crypto to $1 from here!
Kabooooom!!!!
ignatiusrielly35 ignatiusrielly35 39 minutos hace
What's your next prediction? Maybe that the MAA application will never be submitted? How'd that work out for you?

Are you and Mikey the Disgruntled Golfer having lunch at Yips by Hanover Square? Your sponsor won't even take you there? 😂 You boys should unionize. 
AVXL

Su Consulta Reciente

Delayed Upgrade Clock